Advertisement

Molecular & Cellular Toxicology

, Volume 15, Issue 1, pp 19–30 | Cite as

Perinatal exposure to di-ethyl-hexyl phthalate via parenteral route induced polycystic ovarian syndrome-like genetic and pathologic changes in F1 offspring mice

  • Ki Hyun Kil
  • Mee Ran Kim
  • Jang Heub Kim
  • Hyun Hee Cho
Original Paper
  • 12 Downloads

Abstract

Backgrounds

Polycystic ovarian syndrome (PCOS) is the disease of anovulation in women with multifactorial causes. Endocrine-disrupting chemicals such as DEHP (Di-ethyl hexyl phthalate) is thought to play a role in the development of PCOS. The routes of exposure to DEHP including the enteral and parenteral routes, and plastic-containing medical devices are one of the source of high DEHP exposure. We hypothesised perinatal exposure to DEHP via parenteral route induce polycystic ovarian syndrome (PCOS)-like genetic, morphologic, and physical changes in adult mice.

Methods

Pregnant mice were administered DEHP perinatally via parenteral route. The effects of perinatal DEHP exposure was examined in the F1 mice and the results were compared with those obtained for a control group.

Results

Offspring female F1 mice exhibited genetic, pathological, and physical changes in the ovaries, similar to those observed in patients with PCOS, after exposure to DEHP in utero and during lactation.

Conclusion

Perinatal DEHP exposure caused some genetic and pathologic changes in mice, mimicking PCOS in human.

Keywords

DEHP Perinatal period Polycystic ovarian syndrome Microarray 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19, 41–47 (2004).Google Scholar
  2. 2.
    Ovalle, F. & Azziz, R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus. Fertil Steril 77, 1095–1105 (2002).CrossRefGoogle Scholar
  3. 3.
    Teede, H., Deeks, A. & Moran, L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 8, 41 (2010).CrossRefGoogle Scholar
  4. 4.
    Davis, B. J., Maronpot, R. R. & Heindel, J. J. Di-(2-ethylhexyl) phthalate suppresses estradiol and ovulation in cycling rats. Toxicol Appl Pharm 128, 216–223 (1994).CrossRefGoogle Scholar
  5. 5.
    Lovekamp, T. N. & Davis, B. J. Mono-(2-ethylhexyl) phthalate suppresses aromatase transcript levels and estradiol production in cultured rat granulosa cells. Toxicol Appl Pharm 172, 217–224 (2001).CrossRefGoogle Scholar
  6. 6.
    Koo, H. J. & Lee, B. M. Estimated exposure to phthalates in cosmetics and risk assessment. J Toxicol Env Heal A 67, 1901–1914 (2004).CrossRefGoogle Scholar
  7. 7.
    Guo, Y., Wang, L. & Kannan, K. Phthalates and parabens in personal care products from China: concentrations and human exposure. Arch Environ Con Tox 66, 113–119 (2014).CrossRefGoogle Scholar
  8. 8.
    Luo, H., Sun, G., Shi, Y., Shen, Y. & Xu, K. Evaluation of the Di(2-ethylhexyl)phthalate released from polyvinyl chloride medical devices that contact blood. SpringerPlus 3, 58 (2014).CrossRefGoogle Scholar
  9. 9.
    Huygh, J. et al. Considerable exposure to the endocrine disrupting chemicals phthalates and bisphenol-A in intensive care unit (ICU) patients. Environ Int 81, 64–72 (2015).CrossRefGoogle Scholar
  10. 10.
    Sarraj, M. A. & Drummond, A. E. Mammalian foetal ovarian development: consequences for health and disease. Reprod 143, 151–163 (2012).CrossRefGoogle Scholar
  11. 11.
    De Boo, H. A. & Harding, J. E. The developmental origins of adult disease (Barker) hypothesis. Aust NZ J Obst Gynaecol 46, 4–14 (2006).CrossRefGoogle Scholar
  12. 12.
    Cho, H. H., Song, C. M. & Ryu, J. C. Gene expression profile of endometrial carcinoma cells exposed to di-(2-ethylhexyl) phthalate. Mol Cell Toxicol 9, 113–120 (2013).CrossRefGoogle Scholar
  13. 13.
    Cheon, K. Y. et al. Parenteral exposure to DEHP and its effect on the microstructure of bone and Wnt signaling pathway in F2 female mice. BioChip J 10, 223–240 (2016).CrossRefGoogle Scholar
  14. 14.
    Lessey, B. A., Metzger, D. A., Haney, A. F. & McCarty, K. S. Immunohistochemical analysis of estrogen and progesterone receptors in endometriosis: comparison with normal endometrium during the menstrual cycle and the effect of medical therapy. Fertil Steril 51, 409–415 (1989).CrossRefGoogle Scholar
  15. 15.
    Zawadski, J. K. & Dunaif, A. Diagnostic Criteria for Polycystic Ovary Syndrome: Towards a Rational Approach. In: Dunaif, A., Givens, J. R. & Haseltine, F., Eds., Polycystic Ovary Syndrome, Blackwell Scientific, Boston, 377–384 (1992).Google Scholar
  16. 16.
    Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81, 19–25 (2004).Google Scholar
  17. 17.
    Azziz, R. et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab 91, 4237–4245 (2006).CrossRefGoogle Scholar
  18. 18.
    Unluturk, U., Harmanci, A., Kocaefe, C. & Yildiz, B. O. The genetic basis of the polycystic ovary syndrome: A literature review including discussion of PPAR-gamma. PPAR Res 2007, 49109 (2007).CrossRefGoogle Scholar
  19. 19.
    Makowski, L. & Hotamisligil, G. S. The role of fatty acid binding proteins in metabolic syndrome and atherosclerosis. Curr Opin Lipidol 16, 543–548 (2005).CrossRefGoogle Scholar
  20. 20.
    Zimmerman, A. W. & Veerkamp, J. H. New insights into the structure and function of fatty acid-binding proteins. CMLS 59, 1096–1116 (2002).CrossRefGoogle Scholar
  21. 21.
    Wang, J. et al. FABP4: a novel candidate gene for polycystic ovary syndrome. Endocrin 36, 392–396 (2009).CrossRefGoogle Scholar
  22. 22.
    Hu, W. & Qiao, J. Expression and regulation of adipocyte fatty acid binding protein in granulosa cells and its relation with clinical characteristics of polycystic ovary syndrome. Endocrin 40, 196–202 (2011).CrossRefGoogle Scholar
  23. 23.
    Furuhashi, M., Saitoh, S., Shimamoto, K. & Miura, T. Fatty Acid-Binding Protein 4 (FABP4): Pathophysiological insights and potent clinical biomarker of metabolic and cardiovascular diseases. Clin Med Insights Cardiol 8(Suppl 3), 23–33 (2014).Google Scholar
  24. 24.
    Wang, P. et al. Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. Endocrinol 155, 1445–1452 (2014).CrossRefGoogle Scholar
  25. 25.
    O’Brien, T. J. et al. Association between the luteinizing hormone/chorionic gonadotropin receptor (LHCGR) rs4073366 polymorphism and ovarian hyperstimulation syndrome during controlled ovarian hyperstimulation. Reprod Biol Endocrinol 11, 71 (2013).CrossRefGoogle Scholar
  26. 26.
    Escobar-Morreale, H. et al. Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17 alpha. Fertil Steril 62, 521–530 (1994).CrossRefGoogle Scholar
  27. 27.
    Wickenheisser, J. K., Nelson-DeGrave, V. L., Quinn, P. G. & McAllister, J. M. Increased cytochrome P450 17alphahydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol 18, 588–605 (2004).CrossRefGoogle Scholar
  28. 28.
    Petry, C. J. et al. Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. J Steroid Biochem Mol Biol 98, 199–206 (2006).CrossRefGoogle Scholar
  29. 29.
    Deslypere, J. P., Verdonck, L. & Vermeulen, A. Fat tissue: a steroid reservoir and site of steroid metabolism. J Clin Endocrinol Metab 61, 564–709 (1985).CrossRefGoogle Scholar
  30. 30.
    Edman, C. D. & MacDonald, P. C. Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women. Am J Obstet Gynecol 130, 456–461 (1978).CrossRefGoogle Scholar
  31. 31.
    Villavicencio, A. et al. Involvement of Akt, Ras and cell cycle regulators in the potential development of endometrial hyperplasia in women with polycystic ovarian syndrome. Gynecol Oncol 115, 102–107 (2009).CrossRefGoogle Scholar
  32. 32.
    Wood, J. R. et al. The molecular phenotype of polycystic ovary syndrome (PCOS) theca cells and new candidate PCOS genes defined by microarray analysis. J Biol Chem 278, 26380–26390 (2003).CrossRefGoogle Scholar
  33. 33.
    Luu, Y. K. et al. In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model. Med Eng Phys 31, 34–41 (2009).CrossRefGoogle Scholar
  34. 34.
    Androulakis, II. et al. Visceral adiposity index (VAI) is related to the severity of anovulation and other clinical features in women with polycystic ovary syndrome. Clin Endocrinol 81, 426–431 (2014).CrossRefGoogle Scholar
  35. 35.
    Zhang, X. F. et al. Diethylhexyl phthalate exposure impairs follicular development and affects oocyte maturation in the mouse. Environ Mol Mutagen 54, 354–361 (2013).CrossRefGoogle Scholar
  36. 36.
    Grande, S. W. et al. A dose-response study following in utero and lactational exposure to di-(2-ethylhexyl) phthalate (DEHP): reproductive effects on adult female offspring rats. Toxicol 229, 114–122 (2007).CrossRefGoogle Scholar
  37. 37.
    Fagin, D. Toxicology: The learning curve. Nature 490, 462–465 (2012).CrossRefGoogle Scholar
  38. 38.
    Mallow, E. B. & Fox, M. A. Phthalates and critically ill neonates: device-related exposures and non-endocrine toxic risks. J Perinatol 34, 892–897 (2014).CrossRefGoogle Scholar
  39. 39.
    Jaeger, R. J., Weiss, A. L. & Brown, K. Infusion of di-2-ethylhexylphthalate for neonates: a review of potential health risk. J Infus Nurs 28, 54–60 (2005).CrossRefGoogle Scholar

Copyright information

© The Korean Society of Toxicogenomics and Toxicoproteomics and Springer Nature B.V. 2019

Authors and Affiliations

  • Ki Hyun Kil
    • 1
  • Mee Ran Kim
    • 1
  • Jang Heub Kim
    • 1
  • Hyun Hee Cho
    • 1
  1. 1.Department of Ob/Gyn, Seoul St. Mary’s Hospital, College of MedicineThe Catholic University of KoreaBanpo-dong, Seocho-gu, SeoulRepublic of Korea

Personalised recommendations